Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery

International Journal of Gynecological Cancer

Volumn 27, Issue 3, 2017, Pages 514-522

  Bogani, Giorgio ^a   Ditto, Antonino ^a   Martinelli, Fabio ^a   Signorelli, Mauro ^a   Chiappa, Valentina ^a   Lopez, Carlos ^a   Indini, Alice ^a   Leone Roberti Maggiore, Umberto ^b,c   Sabatucci, Ilaria ^a   Lorusso, Domenica ^a   Raspagliesi, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Cervical cancer; Neoadjuvant chemotherapy; Survival; Transfusion

Indexed keywords

ANTINEOPLASTIC AGENT; IRON; RECOMBINANT ERYTHROPOIETIN;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LOCALLY ADVANCED CERVICAL CANCER; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER; ERYTHROCYTE TRANSFUSION; ITALY; MIDDLE AGED; NEOADJUVANT THERAPY; PERIOPERATIVE PERIOD; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

CHEMOTHERAPY, ADJUVANT; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; ITALY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PERIOPERATIVE CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 85014576513     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000902     Document Type: Article

References (34)

1. Pfuntner A, Wier LM, Stocks C. Most Frequent Procedures Performed in U.S. Hospitals, 2011. HCUP Statistical Brief #165. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
2. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006:CD005033.
3. Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg. 2003;237:860-869.
4. Fong Y, Karpeh M, Mayer K, et al. Association of perioperative transfusions with poor outcome in resection of gastric adenocarcinoma. Am J Surg. 1994;167:256-260.
5. Magistrelli P, Antinori A, Crucitti A, et al. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol. 2000;74:36-40.
6. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994;84:1703-1721.
7. Kaplan J, Sarnaik S, Gitlin J, et al. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood. 1984;64:308-310.
8. Hanna N, Fidler IJ. Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst. 1980;65:801-809.
9. Sugita S, Sasaki A, Iwaki K, et al. Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study. Eur J Surg Oncol. 2008;34:339-345.
10. Dionigi G, Rovera F, Boni L, et al. The impact of perioperative blood transfusion on clinical outcomes in colorectal surgery. Surg Oncol. 2007;16:S177-S182.
11. Uccella S, Ghezzi F, Cromi A, et al. Perioperative allogenic blood transfusions and the risk of endometrial cancer recurrence. Arch Gynecol Obstet. 2013;287:1009-1016.
12. Eisenkop SM, Spirtos NM, Montag TW, et al. The clinical significance of blood transfusion at the time of radical hysterectomy. Obstet Gynecol. 1990;76:110-113.
13. De Oliveira GS Jr, Schink JC, Buoy C, et al. The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer. Transfus Med. 2012;22:97-103.
14. Warner LL, Dowdy SC, Martin JR, et al. The impact of perioperative packed red blood cell transfusion on survival in epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23:1612-1619.
15. Monk BJ, Tewari K, Gamboa-Vujicic G, et al. Does perioperative blood transfusion affect survival in patients with cervical cancer treated with radical hysterectomy? Obstet Gynecol. 1995;85:343-348.
16. Lentz SS, Shelton BJ, Toy NJ. Effects of perioperative blood transfusion on prognosis in early-stage cervical cancer. Ann Surg Oncol. 1998;5:216-219.
17. Morris PC, Haugen J, Tomjack J, et al. Blood transfusion and the risk of recurrence in stage IB cervical cancer. Gynecol Oncol. 1995;57:401-406.
18. Spirtos NM, Westby CM, Averette HE, et al. Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a gynecologic oncology group study. Am J Clin Oncol. 2002;25:398-403.
19. Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 2002;20:179-188.
20. Ditto A, Martinelli F, Bogani G, et al. Implementation of laparoscopic approach for type B radical hysterectomy: a comparison with open surgical operations. Eur J Surg Oncol. 2015;41:34-39.
21. Ditto A, Martinelli F, Lo Vullo S, et al. The role of lymphadenectomy in cervical cancer patients: the significance of the number and the status of lymph nodes removed in 526 cases treated in a single institution. Ann Surg Oncol. 2013;20:3948-3954.
22. Raspagliesi F, Bogani G, Martinelli F, et al. Incorporating 3D laparoscopy for the management of locally advanced cervical cancer: a comparison with open surgery. Tumori. 2016;102:393-397.
23. Martinelli F, Bogani G, Ditto A, et al. How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced cervical cancer after neoadjuvant chemotherapy and type C radical hysterectomy? Eur J Surg Oncol. 2015;41:1089-1096.
24. Raspagliesi F, Ditto A, Selvaggi L, et al. A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer. Int J Gynecol Cancer. 2010;20:1569-1575.
25. Lorusso D, Ramondino S, Mancini M, et al. Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma. Int J Gynecol Cancer. 2014;24:729-734.
26. Zanaboni F, Grijuela B, Giudici S, et al. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study. Eur J Cancer. 2013;49:1065-1072.
27. Buda A, Fossati R, Colombo N, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005;23:4137-4145.
28. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177-183.
29. Ferrandina G, Distefano M, Smaniotto D, et al. Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Gynecol Oncol. 2006;103:500-505.
30. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009:CD007303.
31. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532-1542.
32. Lee J, Kim TH, Kim GE, et al. Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage IB-IIB cervical cancer. J Gynecol Oncol. 2016;27:e52.
33. Opelz G, Sengar DP, Mickey MR, et al. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973;5:253-259.
34. Opelz G, Graver B, Terasaki PI. Induction of high kidney graft survival rate by multiple transfusion. Lancet. 1981;1: 1223-1225.